Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 7, 2000, Pages 1876-1884

  Sone, Hirohito ^a   Deo, Baljit K ^a   Kumagai, Arno K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLGLUCOSE; GLUCOSE TRANSPORTER; PROTEIN KINASE C; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BLOOD RETINA BARRIER; CATTLE; CELL CULTURE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLUCOSE TRANSPORT; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RETINA CELL;

3-O-METHYLGLUCOSE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CATTLE; CELL MEMBRANE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GLUCOSE TRANSPORTER TYPE 1; LYMPHOKINES; MONOSACCHARIDE TRANSPORT PROTEINS; PROTEIN KINASE C; RECOMBINANT PROTEINS; RETINAL VESSELS; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034043043     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124:90-96.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. King GL, Kunisaki M, Nishio Y, et al. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes. 1996;45:S105-S108.
4. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
5. King GL, Ishii H, Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int. 1997; 60(suppl):S77-S85.
6. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
7. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes. 1994;43:836-841.
8. Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diab Metab Rev. 1992;8:85-103.
9. Harik SI, Kalaria RN, Whitney PM, et al. Glucose transporters are abundant in cells with "occluding" junctions at the blood-eye barriers. Proc Natl Acad Sci USA. 1990;87:4261-4264.
10. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Erythrocyte/HepG2-type glucose transporter is concentrated in cells of blood-tissue barriers. Biochem Biophys Res Commun. 1990;173:67-73.
11. Mantych GJ, Hageman GS, Devaskar SU. Characterization of glucose transporter isoforms in the adult and developing human eye. Endocrinology. 1993;133:600-607.
12. Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose transporter expression in the human diabetic and nondiabetic eye. Invest Ophthalmol Vis Sci. 1994;35:2887-2889.
13. Bell GI, Kayano T, Buse JB, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13:198-208.
14. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713-725.
15. Takata K, Hirano H, Kasahara M. Transport of glucose across the blood-tissue barriers. Int Rev Cytol. 1997;172:1-53.
16. Kumagai AK. Glucose transport in brain and retina: implications in the management and complications of diabetes Diab Metab Res Rev. 1999;15:261-273.
17. Mueckler M, Caruso C:, Baldwin SA, et al. Sequence and structure of a human glucose transporter. Science. 1985;229:941-945.
18. Pardridge WM, Boado RJ Molecular cloning and gene expression of blood-brain barrier glucose transporter. In: Pardridge WM, ed. The Blood-Brain Barrier: Cellular and Molecular Biology. New York: Raven Press; 1993:395-440.
19. Devaskar SU. The mammalian brain glucose transport system. Adv Exp Med Biol. 1991;293:405-417.
20. Asano T, Shibasaki Y, Lin JL, et al. Expression of the GLUT1 glucose transporter increases thymidine uptake in Chinese hamster ovary cells at low glucose concentrations Cancer Res. 1991; 51:4450-4454.
21. Kumagai AK, Vinores SA, Pardridge WM. Pathological upregulation of the GLUT1 glucose transporter on the inner blood-retinal barrier in diabetes mellitus. Brain Res. 1996;706:313-317.
22. Takagi H, King GL, Aiello LP. Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes, 1998;47: 1480-1488.
23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
24. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
25. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
26. Gerhardinger C, Brown LF, Roy S, et al. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453-1462.
27. Pe'er J, Folberg R, Itin A, et al. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:241-245.
28. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol. 1996;114:971-977.
29. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
30. Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas Lab Invest. 1996;74:819-825.
31. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40:726-730.
32. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of non-proliferative diabetic retinopathy. Am J Ophthalmol. 1997;124: 433-446.
33. Tai PK, Liao JF, Chen EH, et al. Differential regulation of two glucose transporters by chronic growth hormone treatment of cultured 3T3-F442A adipose cells. J Biol Chem. 1990;265:21828-21834.
34. Carter-Su C, Okamoto K. Effect of glucocorticoids on hexose transport in rat adipocytes. Evidence for decreased transporters in the plasma membrane. J Biol Chem. 1985;260:11091-11098.
35. Foley JE, Cushman SW, Salans LB. Glucose transport in isolated rat adipocytes with measurements of L-arabinose uptake. Am J Physiol. 1978;234:E112-E119.
36. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993;42:80-89.
37. Jaffe S, Oliver PD, Farooqui SM, et al. Separation of luminal and abluminal membrane enriched domains from cultured bovine aortic endothelial cells: monoclonal antibodies specific for endothelial cell plasma membranes. Biochim Biophys Acta. 1987;898:37-52.
38. Baldwin SA, Lienhard GE. Purification and reconstitution of glucose transporter from human erythrocytes. Methods Enzymol. 1989;174:39-50.
39. Kumagai AK, Dwyer KJ, Pardridge WM. Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. Biochim. Biophys. Acta. 1994;1193:24-30.
40. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes. 1995;44:1399-1404.
41. Boado RJ, Pardridge WM Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5′-untranslated region. Mol Cell Neurosci. 1990;1:224-232.
42. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43: 1122-1129.
43. Chen SJ, Klann E, Gower MC, et al. Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C. Biochem. 1993;32:1032-1039.
44. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem. 1988; 263:13655-13662.
45. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728-731.
46. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98: 2018-2026.
47. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor Diabetes. 1997;46:1473-1480.
48. Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci. 1997;38:2711-2720.
49. Skou JC, Esmann M. The Na,K-ATPase. J Bioenerg Biomemb. 1992;24:249-261.
50. Shiba T, Inoguchi T. Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
51. Simorre-Pinatel V, Guerrin M, Chollet P, et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci. 1994;35:3393-3400.
52. Boado RJ. Pardridge WM. Measurement of blood-brain barrier GLUT1 glucose transporter and actin mRNA by a quantitative polymerase chain reaction assay. J Neurochem. 1994;62:2085-2090.
53. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem. 1990;265:18051-18054.
54. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription Science. 1987;235:1495-1498.
55. Betz AL, Bowman PD, Goldstein GW. Hexose transport in microvascular endothelial cells cultured from bovine retina. Exp Eye Res. 1983;36:269-277.
56. Knusel B, Michel PP, Schwaber JS, Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci. 1990;10:558-570.
57. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
58. Rea S, James DE. Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles. Diabetes. 1997;46:1667-1677.
59. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44: 98-103.
60. Mandarino LJ, Finlayson J, Hassell JR. High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest Ophthalmol Vis Sci. 1994;35:964-972.
61. Schultz GS, Grant MB. Neovascular growth factors. Eye. 1991;5: 170-180.
62. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes. 1996;45:S77-80.
63. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995; 270:1500-1502.
64. Hammes HP, Brownlee M, Jonczyk A, Sutler A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996;2:529-533.